Oragenics, Inc Email Format

Biotechnology ResearchFlorida, United States11-50 Employees

Oragenics, Inc. is a development-stage biotechnology company based in Tampa, Florida, focused on infectious diseases and neurological conditions. Its lead program, NT-CoV2-1, is an intranasal vaccine candidate intended to prevent COVID-19 and SARS-CoV-2 variants, built on spike protein research licensed from the NIH and NRC with a focus on reducing transmission and patient-friendly administration. The company also pursues a lantibiotics program targeting bacteria that have developed resistance to conventional antibiotics. In May 2026 it announced a letter of intent to license CardioDialysis technology from Sigyn Therapeutics for traumatic brain injury and related chronic neurodegenerative diseases.

Oragenics' activities target clinical researchers and healthcare providers seeking new intranasal therapeutics and neuroprotective strategies. Its ONP-002 intranasal neurosteroid for concussion and mild traumatic brain injury is in Phase IIa trials, and the company has been pursuing IND readiness collaborations and Australian site onboarding to advance its programs.

Get verified Oragenics, Inc emails free

Company overview Employee directory